Deferoxamine Mesylate Injection

Products Affected - Description

Anzemet intravenous injection, Validus Pharmaceuticals
12.5 mg, 0.625 mL single dose vial, 6 count (NDC 00088-1208-06)
500 mg, 25 mL multiple dose vial, 1 count (NDC 00088-1209-26)

Reason for the Shortage

• Validus Pharmaceuticals acquired Anzemet injection from Sanofi US in December 2015.
• Validus Pharmaceuticals has temporarily discontinued Anzemet 12.5 mg/0.625 mL vials and 500 mg/25 mL vials and cannot state if they will bring these products back to market.
  

Available Products

Anzemet intravenous injection, Validus Pharmaceuticals
100 mg, 5 mL single dose vial, 1 count (NDC 00088-1206-32)

Estimated Resupply Dates

Validus Pharmaceuticals has temporarily discontinued Anzemet 12.5 mg/0.625 mL single-use vials and 500 mg/25 mL multidose vials and the company cannot estimate a resupply date.

Related Shortages

• Granisetron Hydrochloride Injection — Resolved

Updated

February 29, 2016, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.